Comparative population pharmacokinetics of lorazepam and midazolam during long-term continuous infusion in critically ill patients

British Journal of Clinical Pharmacology

Volumn 57, Issue 2, 2004, Pages 135-145

  Swart, Eleonora L ^a   Zuideveld, Klaas P ^b   De Jongh, Joost ^c   Danhof, Meindert ^a   Thijs, Lambertus G ^d   Strack Van Schijndel, Robert M J ^d  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c LEIDEN UNIVERSITY   (Netherlands)

^d Department of Pharmacy ^*

Author keywords

Intensive care unit; Lorazepam; Midazolam; Pharmacokinetics

Indexed keywords

DRUG METABOLITE; LORAZEPAM; MIDAZOLAM;

ADULT; ALCOHOL ABUSE; ANALYSIS OF VARIANCE; ANALYTICAL ERROR; ARTICLE; ARTIFICIAL VENTILATION; BLOOD SAMPLING; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CRITICAL ILLNESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG SURVEILLANCE PROGRAM; EXPERIMENTAL MODEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INFUSION; INTENSIVE CARE; LUNG PRESSURE; MALE; PATIENT SELECTION; PREDICTION; PRIORITY JOURNAL; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; STEADY STATE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CRITICAL ILLNESS; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; INFUSIONS, INTRAVENOUS; LORAZEPAM; MALE; MIDAZOLAM; MIDDLE AGED; PLASMA; POSITIVE-PRESSURE RESPIRATION;

EID: 1242306688     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2003.01957.x     Document Type: Article

References (26)

1. Burns AM, Shelly MP, Park GR. The use of sedative agents in critically ill patients. Drugs 1992; 43: 507-15.
2. Aitkenhead AR. Analgesia and sedation in intensive care. Br J Anaesth 1989; 63: 196-206.
3. Swart EL, Strack van Schijndel RJM, van Loenen AC, Thijs LG. Continuous infusion of lorazepam vs midazolam in patients in the intensive care unit: sedation with lorazepam is easier to manage and is more cost-effective. Crit Care Med 1999; 27: 263-9.
4. Mandema JW, Tuk B, van Steveninck AL, Breimer DD, Cohen AF, Danhof M. Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite α-hydroxymidazolam in healthy volunteers. Clin Pharmacol Ther 1992; 51: 715-28.
5. Bauer TM, Ritz R, Haberthür C, Riem Ha H, Hunkeler W, Sleight AJ, Scollo-Lavizzari G, Haefeli WE. Prolonged sedation due to accumulation of conjugated metabolites of midazolam. Lancet 1995; 346: 145-7.
6. Boulieu R, Lehmann B, Salord F, Fisher C, Morlet D. Pharmacokinetics of midazolam and its main metabolite 1-hydroxymidazolam in intensive care patients. Eur J Drug Metab Pharmacokinet 1998; 23: 255-8.
7. Verbeeck RK, Branch RA, Wilkinson GR. Drug metabolites in renal failure. Clin Pharmacokinet 1981; 6: 329-45.
8. Park GR. Molecular mechanisms of drug metabolism in the critically ill. Br J Anaesth 1996; 77: 32-49.
9. Barr J, Zomorodi K, Bertaccini EJ, Shafer SL, Geller E. A double-blind, randomized comparison of IV lorazepam versus midazolam for sedation of ICU patients via a pharmacologic model. Anesthesiology 2001; 95: 286-98.
10. Knaus WA, Draoer EA, Wagner DP, Zimmerman JE. APACHE II, a severity of disease classification system. Crit Care Med 1985; 13: 818-29.
11. Vletter AA, Burm AGL, Breimer LTM, Spierdijk J. High performance liquid chromatographic assay of midazolam and flumazenil simultaneously in human plasma. J Chromatogr Biomed Appl 1990; 530: 177-85.
12. Kraus JW, Desmond PV, Marshall JP, Johnson RF, Schenker S, Wilkinson GR. Effects of aging and liver disease on disposition of lorazepam. Clin Pharmacol Ther 1978; 24: 411-19.
13. Macgilchrist AJ, Birnie GG, Cook A, Scobie G, Murray T, Watkinson G, Brodie MJ. Pharmacokinetics and pharmacodynamics of intravenous midazolam in patients with severe alcoholic cirrhosis. Gut 1986; 27: 190-5.
14. Albrecht S, Ihmsen H, Hering W, Geisslinger C, Dingemanse J, Schwilden H, Schüttler J. The effect of age on the Pharmacokinetics and pharmacodynamics of midazolam. Clin Pharmacol Ther 1999; 65: 630-9.
15. Greenblatt DJ, Divoll Allen M, Locniskar A, Harmatz JS, Shader RI. Lorazepam kinetics in the elderly. Clin Pharmacol Ther 1979; 26: 103-13.
16. McKindley DS, Hanes S, Boucher BA. Hepatic drug metabolism in critical illness. Pharmacotherapy 1998; 18: 759-78.
17. Richard C, Berdeaux A, Delion F, Riou B, Rimailho A, Giudicelli JF, Auzzepy P. Effect of mechanical ventilation on hepatic drug pharmacokinetics. Chest 1986; 90: 837-41.
18. Bonnet F, Richard C, Glaser P, Lafay M, Guesde R. Changes in hepatic blood flow induced by continuous positive pressure ventilation in critically ill patients. Crit Care Med 1982; 10: 703-5.
19. Thummel KE, O'Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD, Wilkinson GR. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 1996; 59: 491-502.
20. Shelly MP, Mendel L, Park GR. Failure of critically ill patients to metabolise midazolam. Anaesthesia 1987; 42: 619-26.
21. Greenblatt DJ, Shader RI, Franke K, MacLauglin DS, Harmatz JS, Divoll Allen M, Werner A, Woo E. Pharmacokinetics and bioavailability of intravenous, intramuscular, and oral lorazepam in humans. J Pharm Sci 1979; 68: 57-63.
22. Driessen JJ, Vree TB, Guelen PJM. The effects of acute changes in renal function on the pharmacokinetics of midazolam during long-term infusion in ICU patients. Acta Anaesth Belg 1991; 42: 49-55.
23. von Moltke LL, Greenblatt DJ, Schmider J, Duan SX, Wright CE, Harmatz JS, Shader RI. Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents. J Clin Pharmacol 1996; 36: 783-91.
24. Ahonen J, Olkkola KT, Takala A, Neuvonen PJ. Interaction between fluconazole and midazolam in intensive care patients. Acta Anaesthesiol Scand 1999; 43: 509-14.
25. Backman JT, Olkkola KT, Aranko K, Himberg JJ, Neuvonen PJ. Dose of midazolam should be reduced during diltiazem and verapamil treatments. Br J Clin Pharmacol 1994; 37: 221-5.
26. Olkkola KT, Aranko K, Luurila H, Hiller A, Saarnivaara L, Himberg JJ, Neuvonen PJ. A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther 1993; 53: 298-305.